Imatinib-d8 (CAS 1092942-82-9)
Alternate Names:
4-[(4-Methyl-1-piperazinyl-2,2,3,3,5,5,6,6-d8)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide
Application:
Imatinib-d8 is a deuterated tyrosine kinase inhibitor.
CAS Number:
1092942-82-9
Molecular Weight:
501.65
Molecular Formula:
C29H23D8N7O
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Imatinib-d8 is a deuterium-labeled analog of imatinib, where eight hydrogen atoms have been replaced with deuterium. This compound is frequently used in chemical research to investigate the metabolic fate of imatinib through mass spectrometry, allowing for more precise tracking due to the increased mass of the molecule. It serves as an internal standard to ensure accurate quantification of imatinib in biological samples by compensating for potential analytical variations. Research involving Imatinib-d8 primarily focuses on enhancing the understanding of the kinetics of imatinib. Moreover, it is instrumental in studying the metabolic pathways and interactions of imatinib at a molecular level, as well as in the determination of its bioavailability and distribution in research applications.
Imatinib-d8 (CAS 1092942-82-9) References
- Determination of imatinib plasma levels in patients with chronic myeloid leukemia by high performance liquid chromatography-ultraviolet detection and liquid chromatography-tandem mass spectrometry: methods' comparison. | Awidi, A., et al. 2010. Leuk Res. 34: 714-7. PMID: 19744707
- Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes. | Nebot, N., et al. 2010. Br J Pharmacol. 161: 1059-69. PMID: 20977456
- Paper spray ionization devices for direct, biomedical analysis using mass spectrometry. | Yang, Q., et al. 2012. Int J Mass Spectrom. 312: 201-207. PMID: 22350566
- Imatinib assay by high-performance liquid chromatography in tandem mass spectrometry with solid-phase extraction in human plasma. | Moreno, JM., et al. 2013. Biomed Chromatogr. 27: 502-8. PMID: 23034891
- Comment on: Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance. | Simpson, DC. 2013. Rev Bras Hematol Hemoter. 35: 83-4. PMID: 23741181
- DBS sampling in imatinib therapeutic drug monitoring: from method development to clinical application. | Antunes, MV., et al. 2015. Bioanalysis. 7: 2105-17. PMID: 26327189
- Direct sampling mass spectrometry for clinical analysis. | Pu, F., et al. 2019. Analyst. 144: 1034-1051. PMID: 30520890
- Quantitative Mass Spectrometry Imaging Reveals Mutation Status-independent Lack of Imatinib in Liver Metastases of Gastrointestinal Stromal Tumors. | Abu Sammour, D., et al. 2019. Sci Rep. 9: 10698. PMID: 31337874
- Pseudo-Multiple Reaction Monitoring (Pseudo-MRM) Mode on the 'Brick' Mass Spectrometer, Using the Grid-SWIFT Waveform. | Xu, Z., et al. 2019. Anal Chem. 91: 13838-13846. PMID: 31560203
- Development and validation of an LC-MS/MS method for the quantification of imatinib and imatinib-d8 in human plasma for the support of an absolute bioavailability microdose trial. | Roosendaal, J., et al. 2020. Pharmazie. 75: 136-141. PMID: 32295689
- A mini mass spectrometer with a low noise Faraday detector. | Tang, Y., et al. 2020. Analyst. 145: 3892-3898. PMID: 32297893
- Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose. | Roosendaal, J., et al. 2020. Eur J Clin Pharmacol. 76: 1075-1082. PMID: 32430518
- Safety, tolerability, and pharmacokinetics of single and multiple topical ophthalmic administration of imatinib mesylate in healthy subjects. | Na, JY., et al. 2022. Clin Transl Sci. 15: 1123-1130. PMID: 35133064
- Determination of olverembatinib in human plasma and cerebrospinal fluid by an LC-MS/MS method: Validation and clinical application. | Xiang, D., et al. 2023. J Pharm Biomed Anal. 230: 115382. PMID: 37060798
Inhibitor of:
Tyrosine Kinase.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Imatinib-d8, 1 mg | sc-488072 | 1 mg | $556.00 | |||
Imatinib-d8, 10 mg | sc-488072A | 10 mg | $4085.00 |